Sarcoma  >>  conatumumab (AMG 655)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
conatumumab (AMG 655) / Amgen
NCT01327612 / 2010-022270-14: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed
2
12
Europe, US
Modified FOLFOX6, Oxaliplatin-Leucovorin-Fluorouracil chemotherapy, Conatumumab, AMG 655, Ganitumab, AMG 479, Bevacizumab, Avastin
Amgen
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
02/20
02/20
NCT00626704: Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Completed
1b/2
134
US, Europe
AMG 655, Conatumumab, Placebo, Doxorubicin
Amgen
Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma, Soft Tissue Sarcoma
08/09
03/11
NCT00819169 / 2008-005074-12: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Terminated
1b/2
89
US, Europe
AMG 479, AMG 655, AMG 655 is also known as conatumumab.
NantCell, Inc.
Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Solid Tumors
10/10
10/11

Download Options